Сyclooxygenase-2 Inhibitor Parecoxib Reduces LPS-Induced Activation of BV2 Microglia Cells

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Microglia play a crucial role in neuroinflammation.
• Lipopolysaccharide (LPS) is a potent activator of microglial cells, inducing inflammatory responses.
• The NLRP3 inflammasome is a key mediator of inflammation in microglia.

Purpose of the Study:

• To investigate the inhibitory effect of parecoxib, a cyclooxygenase-2 (COX-2) inhibitor, on LPS-induced activation of BV2 microglial cells.
• To determine if parecoxib modulates the NLRP3 inflammasome pathway in activated microglia.

Main Methods:

• BV2 microglial cells were treated with LPS (1 μg/ml) to induce activation.
• Cells were pretreated with an optimal dose of parecoxib (80 μmol/liter) before LPS exposure.
• Cell morphology, proliferation, and the expression of NLRP3, caspase-1, pro-caspase-1, and IL-1β were assessed.

Main Results:

• LPS induced significant morphological changes and reduced proliferation in BV2 cells.
• Parecoxib pretreatment prevented LPS-induced alterations in cell morphology and proliferation.
• LPS significantly increased NLRP3 inflammasome activation and the expression of NLRP3, caspase-1, pro-caspase-1, and IL-1β.
• Parecoxib pretreatment effectively inhibited these LPS-induced increases in inflammatory markers.

Conclusions:

• Parecoxib demonstrates significant inhibitory effects on LPS-induced BV2 microglial activation.
• Parecoxib likely exerts its protective effects by inhibiting the activation of the NLRP3 inflammasome pathway.
• These findings suggest parecoxib as a potential therapeutic agent for neuroinflammatory conditions involving microglial activation.